What is the purpose of the $300 million Term Loan Agreement?

The $300 million Term Loan Agreement was entered into by Gilead Biopharmaceutics Ireland Corporation. The primary purpose of drawing on this loan was to facilitate the repatriation of $280 million in foreign earnings to Gilead Sciences, Inc., under the provisions of The American Jobs Creation Act of 2004.

What is the expected financial impact of repatriating foreign earnings?

Gilead Sciences anticipates that approximately $240 million of the repatriated earnings will qualify for the 85 percent dividend received deduction under the Internal Revenue Code. Additionally, the company expects a one-time tax benefit of approximately $25 million resulting from this repatriation.

What is the purpose of the $200 million Credit Agreement?

The $200 million Credit Agreement entered into by Gilead Sciences, Inc. is primarily for working capital requirements and general corporate purposes of Gilead and its subsidiaries. It also allows for the payment of fees and expenses associated with the agreement.

When do these new credit facilities mature?

Both the $300 million Term Loan Agreement and the $200 million Credit Agreement have a maturity date of December 20, 2010.

GILD 8-K: Material Agreements & Financial Events

Summary

Gilead Sciences, Inc. (GILD) announced through an 8-K filing on December 27, 2005, the establishment of significant new credit facilities. Specifically, Gilead Biopharmaceutics Ireland Corporation entered into a $300 million Term Loan Agreement, with proceeds used to repatriate $280 million in foreign earnings. Gilead anticipates a tax benefit of approximately $25 million from this repatriation, with about $240 million qualifying for a substantial dividend received deduction under the American Jobs Creation Act of 2004. This move suggests a strategic decision to access and utilize foreign cash reserves for domestic operations or other corporate purposes. In addition to the term loan, Gilead Sciences, Inc. secured a $200 million revolving Credit Agreement for working capital and general corporate needs. Both credit facilities mature on December 20, 2010, and bear interest based on LIBOR or a base rate with specified margins. These agreements underscore Gilead's active approach to managing its capital structure and leveraging its financial resources. The company also included customary covenants and events of default typical for such credit arrangements, with detailed agreements filed as exhibits.

Key Highlights

1Gilead Biopharmaceutics Ireland Corporation secured a $300 million Term Loan Agreement on December 21, 2005.
2Proceeds from the Term Loan Agreement were used to repatriate $280 million in foreign earnings to Gilead Sciences, Inc. on December 27, 2005.
3Gilead anticipates a one-time tax benefit of approximately $25 million from the repatriation, with a significant portion eligible for a dividend received deduction.
4Gilead Sciences, Inc. also entered into a $200 million revolving Credit Agreement for working capital and general corporate purposes.
5Both the Term Loan Agreement and the Credit Agreement mature on December 20, 2010.
6Interest rates for both agreements are based on LIBOR plus a margin or a defined 'base rate'.
7Customary representations, warranties, covenants, and events of default are included in both agreements.

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (Dec 27, 2005)

Summary

Key Highlights

Frequently Asked Questions